Medifast Analyst Ratings
Medifast Analyst Ratings
While ratings are subjective and will change, the latest Medifast (MED) rating was a initiated with a price target of $0.00 to $82.00. The current price Medifast (MED) is trading at is $68.88, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | 19.05% | Stephens & Co. | → $82 | Initiates Coverage On | → Equal-Weight |
| 08/08/2023 | 16.14% | DA Davidson | $93 → $80 | Maintains | Neutral |
| 07/31/2023 | 35.02% | DA Davidson | $75 → $93 | Maintains | Neutral |
| 05/02/2023 | 3.08% | DA Davidson | $94 → $71 | Maintains | Neutral |
| 02/22/2023 | 36.47% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 53.89% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 303.6% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 117.77% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 411.03% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 395.06% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 406.68% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 473.46% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 338.44% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 284.73% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 246.98% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 197.62% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 138.1% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | 24.85% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | 20.5% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | 7.43% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 88.73% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 213.59% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 10/13/2023 | 19.05% | Stephens & Co. | → 82 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 08/08/2023 | 16.14% | DA Davidson | 93 美元 → 80 美元 | 維護 | 中立 |
| 07/31/2023 | 35.02% | DA Davidson | 75 美元 → 93 美元 | 維護 | 中立 |
| 05/02/2023 | 3.08% | DA Davidson | 94 美元 → 71 美元 | 維護 | 中立 |
| 02/22/2023 | 36.47% | DA Davidson | 106 美元 → 94 美元 | 維護 | 中立 |
| 2022 年 4 月 11 日 | 53.89% | DA Davidson | 278 美元 → 106 美元 | 降級 | 買入 → 中性 |
| 08/04/2022 | 303.6% | DA Davidson | 352 美元 → 278 美元 | 維護 | 購買 |
| 08/04/2022 | 117.77% | 傑富瑞集團 | 345 美元 → 150 美元 | 降級 | 買入 → 持有 |
| 06/02/2022 | 411.03% | DA Davidson | 341 美元 → 352 美元 | 維護 | 購買 |
| 2022 年 2 月 24 日 | 395.06% | DA Davidson | 349 美元 → 341 美元 | 維護 | 購買 |
| 2021 年 8 月 11 日 | 406.68% | DA Davidson | 395 美元 → 349 美元 | 維護 | 購買 |
| 2021 年 5 月 5 日 | 473.46% | DA Davidson | 302 美元 → 395 美元 | 維護 | 購買 |
| 2021 年 2 月 26 日 | 338.44% | DA Davidson | 239 美元 → 302 美元 | 維護 | 購買 |
| 2021 年 1 月 25 日 | 284.73% | 傑富瑞集團 | 205 美元 → 265 美元 | 升級 | 持有 → 買入 |
| 2021 年 12 月 1 日 | 246.98% | DA Davidson | 205 美元 → 239 美元 | 維護 | 購買 |
| 2020 年 5 月 11 日 | 197.62% | DA Davidson | 180 美元 → 205 美元 | 升級 | 中性 → 買入 |
| 06/25/2020 | 138.1% | B. 萊利證券 | → 164 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 6 月 5 日 | 24.85% | DA Davidson | 83 美元 → 86 美元 | 維護 | 中立 |
| 02/27/2020 | 20.5% | DA Davidson | 74 美元 → 83 美元 | 維護 | 中立 |
| 11/08/2019 | 7.43% | DA Davidson | 250 美元 → 74 美元 | 降級 | 買入 → 中性 |
| 2019 年 7 月 25 日 | 88.73% | 傑富瑞集團 | → 130 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/27/2019 | 213.59% | Sidoti & Co. | 211 美元 → 216 美元 | 維護 | 購買 |
| 11/08/2018 | — | Sidoti & Co. | 升級 | 中性 → 買入 |
What is the target price for Medifast (MED)?
Medifast (MED) 的目標價格是多少？
The latest price target for Medifast (NYSE: MED) was reported by Stephens & Co. on October 13, 2023. The analyst firm set a price target for $82.00 expecting MED to rise to within 12 months (a possible 19.05% upside). 6 analyst firms have reported ratings in the last year.
Stephens & Co. 於2023年10月13日公佈了Medifast（紐約證券交易所代碼：MED）的最新目標股價。該分析公司將目標股價定爲82.00美元，預計MED將在12個月內上漲至19.05％（可能上漲19.05％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Medifast (MED)?
分析師對Medifast（MED）的最新評級是多少？
The latest analyst rating for Medifast (NYSE: MED) was provided by Stephens & Co., and Medifast initiated their equal-weight rating.
Medifast（紐約證券交易所代碼：MED）的最新分析師評級由Stephens & Co. 提供，Medifast啓動了同等權重評級。
When is the next analyst rating going to be posted or updated for Medifast (MED)?
Medifast (MED) 的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Medifast的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Medifast的最後一次評級是在2023年10月13日提交的，因此你應該預計下一個評級將在2024年10月13日左右公佈。
Is the Analyst Rating Medifast (MED) correct?
分析師對Medifast (MED) 的評級正確嗎？
While ratings are subjective and will change, the latest Medifast (MED) rating was a initiated with a price target of $0.00 to $82.00. The current price Medifast (MED) is trading at is $68.88, which is within the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的Medifast（MED）評級最初的目標價爲0.00美元至82.00美元。Medifast（MED）目前的交易價格爲68.88美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。